Cargando…
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors
Tadalafil is a clinically approved phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction and pulmonary arterial hypertension. It contains two chiral carbons, and the marketed isomer is the 6R, 12aR isomer with a methyl substituent on the terminal nitrogen of the piperazinedione rin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064235/ https://www.ncbi.nlm.nih.gov/pubmed/28117310 http://dx.doi.org/10.3390/scipharm84030428 |
_version_ | 1782460114528108544 |
---|---|
author | Elhady, Ahmed K. Sigler, Sara C. Noureldin, Nazih Canzoneri, Joshua C. Ahmed, Nermin S. Piazza, Gary A. Abadi, Ashraf H. |
author_facet | Elhady, Ahmed K. Sigler, Sara C. Noureldin, Nazih Canzoneri, Joshua C. Ahmed, Nermin S. Piazza, Gary A. Abadi, Ashraf H. |
author_sort | Elhady, Ahmed K. |
collection | PubMed |
description | Tadalafil is a clinically approved phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction and pulmonary arterial hypertension. It contains two chiral carbons, and the marketed isomer is the 6R, 12aR isomer with a methyl substituent on the terminal nitrogen of the piperazinedione ring. In this report, tadalafil analogues with an extended hydrophilic side chain on the piperazine nitrogen were designed to interact with particular hydrophilic residues in the binding pocket. This leads to analogues with moderate inhibitory activity on phosphodiesterase-5, even for isomers in which chiral carbons are of the S configuration. |
format | Online Article Text |
id | pubmed-5064235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-50642352016-10-27 Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors Elhady, Ahmed K. Sigler, Sara C. Noureldin, Nazih Canzoneri, Joshua C. Ahmed, Nermin S. Piazza, Gary A. Abadi, Ashraf H. Sci Pharm Article Tadalafil is a clinically approved phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction and pulmonary arterial hypertension. It contains two chiral carbons, and the marketed isomer is the 6R, 12aR isomer with a methyl substituent on the terminal nitrogen of the piperazinedione ring. In this report, tadalafil analogues with an extended hydrophilic side chain on the piperazine nitrogen were designed to interact with particular hydrophilic residues in the binding pocket. This leads to analogues with moderate inhibitory activity on phosphodiesterase-5, even for isomers in which chiral carbons are of the S configuration. MDPI 2015-09-26 2016 /pmc/articles/PMC5064235/ /pubmed/28117310 http://dx.doi.org/10.3390/scipharm84030428 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Elhady, Ahmed K. Sigler, Sara C. Noureldin, Nazih Canzoneri, Joshua C. Ahmed, Nermin S. Piazza, Gary A. Abadi, Ashraf H. Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors |
title | Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors |
title_full | Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors |
title_fullStr | Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors |
title_full_unstemmed | Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors |
title_short | Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors |
title_sort | structure-based design of novel tetrahydro-beta-carboline derivatives with a hydrophilic side chain as potential phosphodiesterase inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064235/ https://www.ncbi.nlm.nih.gov/pubmed/28117310 http://dx.doi.org/10.3390/scipharm84030428 |
work_keys_str_mv | AT elhadyahmedk structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors AT siglersarac structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors AT noureldinnazih structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors AT canzonerijoshuac structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors AT ahmednermins structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors AT piazzagarya structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors AT abadiashrafh structurebaseddesignofnoveltetrahydrobetacarbolinederivativeswithahydrophilicsidechainaspotentialphosphodiesteraseinhibitors |